New Pfizer anti-viral and ivermectin

Pharmacodynamic analyses that show that the new Pfizer antiviral works in the same way as ivermectin -- as a SARS-CoV-2-3CL protease inhibitor. Plenty of links attached to the video to back the claim.

View here (Youtube, Nov 9, 2021)

Sinovac cuts Covid-19 death risk by 84%, AZ and Pfizer by over 90%: Malaysia survey on 1.26m people

‘The Sinovac vaccine can reduce the risk of death among Covid-19 patients by up to 84%, the health ministry said today. Citing data from the real-world evaluation of Covid-19 vaccines under the Malaysia national Covid-19 immunisation programme (RECoVaM), the ministry said the Pfizer jab decreased the risk of death by 93%.

‘In a Twitter post, it said the AstraZeneca vaccine showed the best result, with the lowest rate of “breakthrough deaths”, with the study finding that the jab reduced the risk of deaths among Covid-19 patients by 96%. This was based on a survey led by the health ministry’s Institute for Clinical Research (ICR) on 1,261,270 individuals.’

Read here (Free Malaysia Today, Sept 24, 2021)

Pfizer announces positive results for Covid-19 vaccine for children

‘Pfizer and BioNTech on September 20 announced positive results from a Phase 2/3 trial of their SARS-CoV-2 vaccine in children aged 5 to 11 years. The researchers found that a 2-dose regimen of 10µg doses administered 21 days apart demonstrated a favorable safety profile and robust neutralizing antibody response. The findings—which are neither published nor peer-reviewed—are a crucial step toward a SARS-CoV-2 vaccine becoming available for younger children, and the companies expect to submit an application to the US FDA for the vaccine’s authorization for that age group by the end of September. US regulators have issued warnings to the general public to wait for authorization before seeking vaccination for younger children, as the full adult dose of 30µg may put children at a higher risk for adverse side effects, including myocarditis.

‘The trial included nearly 2,300 children, and two-thirds of them in the vaccine group. The vaccinated children also were compared with a separate cohort of 16-25-year-old individuals who received the full adult course of the vaccine (2 doses of 30µg). The trial found that the neutralizing antibody response was similar between both vaccinated groups, with the neutralizing antibody levels within 5% of each other. Both groups also experienced similar post-vaccination adverse events.’

Read here (Pfizer news release) and here (Stat News, Sept 20, 2021)

Covid-19 deaths among vaccinated rare, mostly Sinovac recipients

‘These deaths of the fully vaccinated, that occurred between June 7 and Sept 6, were mainly senior citizens (744; 80.6 percent), had comorbidities (750; 81.3 percent) - usually both (605; 65.6 percent). Deaths among those below 60 with no comorbidities only accounted for 33 cases (3.6 percent).

‘Based on Malaysiakini's analysis of the data, Sinovac vaccine recipients account for 710 out of 922 of these deaths (77.0 percent), even though Sinovac vaccine recipients only make up 51.5 percent of fully vaccinated people as of Sept 6 including the 14-day period after the second dose. In comparison, Pfizer vaccine recipients account for 206 deaths (22.3 percent) while accounting for 43.6 percent of the fully vaccinated population in Malaysia. 

‘In other words, there are 10.11 vaccine breakthrough deaths for every 100,000 people fully vaccinated with the Sinovac vaccine, and 3.47 per 100,000 for Pfizer recipients.’

Read here (Malaysiakini via YahooNews, Sept 10, 2021) 

Singapore SARS survivors yield hope for Covid super vaccine

‘Survivors who lived through the SARS crisis in Singapore nearly two decades ago may yield hope for the development of a super vaccine to combat potent Covid-19 variants and even other coronaviruses, new research shows.

‘Scientists from the city-state’s Duke-NUS Medical School and National Centre for Infectious Diseases (NCID) have found “highly potent functional antibodies” in people who had severe acute respiratory syndrome and were vaccinated with Pfizer-BioNTech’s shots for Covid-19.’

Read here (Free Malaysia Today, August 21, 2021)

Put people before profits for progress

‘Millions of people are expected to die due to delayed and unaffordable access to COVID-19 tests, treatment, personal protective equipment and vaccines. Urgent cooperation is desperately needed to save lives and livelihoods for all.’

This story is well argued and contains several relevant and informative links under the following subheadings:

• Vaccine apartheid
• Pfizer profits
• What the pandemic demands
• Technology transfer needed
• What the world needs now

Read here (IPS News, May 18, 2021)

The hot-person vaccine

‘The internet has decided that Pfizer is significantly cooler than Moderna—but why?...

‘Large differences in access aren’t limited to certain brands, and some degree of “us versus them” applies across all of the available shots. White Americans continue to have higher vaccination rates than Black and Hispanic Americans, for example. And according to a vaccine-equity project run out of Duke University’s Global Health Innovation Center, high-income countries have already purchased more than half of the world’s available vaccine doses.

‘Seen in that context, ironic Pfizer elitism may feel uncomfortably close to actual elitism. Another vaccine-culture TikTok that went viral paired each brand with its equivalent cellphone—the iPhone for Pfizer, a recent-looking Android model for Moderna, an early 2010s pay-as-you-go Firefly phone for Johnson & Johnson, and a truly ancient Nokia for AstraZeneca. The video compared the slim but tangible differences between Pfizer and Moderna to the silly, perennial debate over whether iPhone users are snobby and judgmental toward people whose texts show up as “green bubbles.” For some commenters, this was a step too far. “Classism is disgusting,” one responded. “Not westerners fighting over which vaccine is best,” another wrote with a sobbing emoji.’

Read here (The Atlantic, Apr 30, 2021)

Revealed: How a single pill home cure for Covid could be available this year

‘At two anonymous Pfizer buildings, one in the US and one in Belgium, a remarkable experiment is under way. Up to 60 volunteers, all clean-living adults aged between 18 and 60, are being given the first pill specifically designed to stop SARS-CoV-2.

‘If the trial is successful, it is just possible that a home cure for Covid-19 will become available later this year. The Prime Minister, who announced the formation of a UK Antivirals Taskforce last week specifically to invest in such products, will no doubt be scanning his text messages for early updates.

‘The molecule being tested is a bespoke antiviral codenamed PF 07321332. Classed as a "protease inhibitor", it has been formulated to attack the "spine" of the SARS-Cov-2 virus and stop it replicating in our noses, throats and lungs. It was protease inhibitors that turned the tide on the spread of HIV in the UK and around the world. Now researchers hope they may be on the brink of a similar pandemic-busting breakthrough.’

Read here (The Telegraph, Apr 24, 2021)

Kati Kariko helped shield the world from the coronavirus

‘Collaborating with devoted colleagues, Dr. Kariko laid the groundwork for the mRNA vaccines turning the tide of the pandemic...

‘Now Katalin Kariko, 66, known to colleagues as Kati, has emerged as one of the heroes of Covid-19 vaccine development. Her work, with her close collaborator, Dr. Drew Weissman of the University of Pennsylvania, laid the foundation for the stunningly successful vaccines made by Pfizer-BioNTech and Moderna.

‘For her entire career, Dr. Kariko has focused on messenger RNA, or mRNA — the genetic script that carries DNA instructions to each cell’s protein-making machinery. She was convinced mRNA could be used to instruct cells to make their own medicines, including vaccines.

‘But for many years her career at the University of Pennsylvania was fragile. She migrated from lab to lab, relying on one senior scientist after another to take her in. She never made more than $60,000 a year.’

Read here (New York Times, Apr 7, 2021)

Why you can't compare Covid-19 vaccines

‘In the US, the first two available Covid-19 vaccines were the ones from Pfizer/BioNTech and Moderna. Both vaccines have very high "efficacy rates," of around 95%. But the third vaccine introduced in the US, from Johnson & Johnson, has a considerably lower efficacy rate: just 66%.

‘Look at those numbers next to each other, and it's natural to conclude that one of them is considerably worse. Why settle for 66% when you can have 95%? But that isn't the right way to understand a vaccine's efficacy rate, or even to understand what a vaccine does. And public health experts say that if you really want to know which vaccine is the best one, efficacy isn't actually the most important number at all.’

View here (Vox, Youtube, Mar 20, 2021)

Michael Yeadon: The ex-Pfizer scientist who became an anti-vax hero

‘Late last year, a semi-retired British scientist co-authored a petition to Europe’s medicines regulator. The petitioners made a bold demand: Halt COVID-19 vaccine clinical trials. Even bolder was their argument for doing so: They speculated, without providing evidence, that the vaccines could cause infertility in women.

‘The document appeared on a German website on Dec.1. Scientists denounced the theory. Regulators weren’t swayed, either: Weeks later, the European Medicines Agency approved the European Union’s first COVID-19 shot, co-developed by Pfizer Inc. But damage was already done.

‘Social media quickly spread exaggerated claims that COVID-19 jabs cause female infertility. Within weeks, doctors and nurses in Britain began reporting that concerned women were asking them whether it was true, according to the Royal College of Obstetricians & Gynaecologists. In January, a survey by the Kaiser Family Foundation (KFF), a non-profit organization, found that 13% of unvaccinated people in the United States had heard that “COVID-19 vaccines have been shown to cause infertility.”

‘What gave the debunked claim credibility was that one of the petition’s co-authors, Michael Yeadon, wasn’t just any scientist. The 60-year-old is a former vice president of Pfizer, where he spent 16 years as an allergy and respiratory researcher. He later co-founded a biotech firm that the Swiss drugmaker Novartis purchased for at least $325 million.’

Read here (Reuters, Mar 18, 2021)

Khairy welcomes private sector procuring approved Covid-19 vaccines

“With regards to the purchase of vaccines by the private sector, as I have mentioned yesterday, most of the vaccine manufacturers only carry out negotiations with governments,” Khairy responded to Najib in a comment on his Facebook post...

“But if there are private parties who are able to carry out negotiations with vaccine manufacturers, especially those that have received approval from the NPRA (National Pharmaceutical Regulatory Agency) (Pfizer, AstraZeneca, and Sinovac), please do so. I really welcome it,” added the science, technology and innovation minister. 

‘Previously, Malaysian-based pharmaceutical company Pharmaniaga Bhd announced that it planned to sell some of its Sinovac vaccine doses to the private sector. Pharmaniaga is undertaking the fill-and-finish processing of Sinovac’s vaccine. Solution Biologics, the distributor of Chinese CanSino’s vaccine, has also expressed plans to supply private health care providers with the vaccine, on top of selling 3.5 million doses to the Malaysian government.’ 

Read here (Code Blue, Mar 10, 2021)

From Pfizer to Moderna: Who's making billions from Covid-19 vaccines?

‘Among the biggest winners will be Moderna and Pfizer – two very different US pharma firms which are both charging more than $30 per person for the protection of their two-dose vaccines. While Moderna was founded just 11 years ago, has never made a profit and employed just 830 staff pre-pandemic, Pfizer traces its roots back to 1849, made a net profit of $9.6bn last year and employs nearly 80,000 staff.

‘But other drugmakers, such as the British-Swedish AstraZeneca and the US pharma Johnson & Johnson, have pledged to provide their vaccines on a not-for-profit basis until the pandemic comes to an end.’

Also carried in this story are: Sinovac, Sputnik V, Novavax, CureVac 

Read here (The Guardian, Mar 6, 2021)

Finding an ultimate vaccine to fight the mutating “emperor” virus

‘We are commenting on the shocking CNN website report (March 2), headlined “All our recent progress with COVID-19 could be wiped out by variants, CDC director says”. The first two paragraphs (below) are enough to sum up the CNN report: “The US is at risk of losing all its recent gains in the battle against COVID-19 as highly contagious variants take advantage of Americans getting lax with safety measures... “Please hear me clearly: At this level of cases with variants spreading, we stand to completely lose the hard-earned ground we have gained,” said Dr Rochelle Walensky, director of the US centers for Disease Control and Prevention (CDC).”...

‘With new variants, serious doubts are suggested by the CNN report on whether this “vaccine” [mRNA], the first in the global market, would work, even if safety factor is put aside. Nevertheless, there are safe and workable vaccines, using tried and tested technologies like using inactivated or attenuated virus from nature to stimulate the body to produce anti-body response. Even the adenovirus viral vector technology, tried and tested for Ebola, appears to be safer than mRNA.

‘There are also safe and good alternatives, like the anti-viral “broad spectrum” drug Ivermectin, which can destroy the new variants. In the meantime, it is vital that we improve our body immunity against COVID-19 by taking Vitamin C with zinc, Vitamin D, minerals and trace elements needed, explore proven traditional and complimentary medicines, and maintain established standard operating procedures (SOPs) of physical distancing, wearing surgical masks and personal hygiene in public places.’

Read here (Focus Malaysia, Mar 4, 2021)

Malaysia approves Sinovac, AstraZeneca Covid-19 vaccines for use

‘Malaysia on Tuesday (Mar 2) granted conditional approval for the use of vaccines made by UK firm AstraZeneca and China's Sinovac, just days after launching its nationwide COVID-19 inoculation programme. Malaysia began its vaccination drive on Feb 24 using a shot developed by US drugmaker Pfizer and German partner BioNTech, as it tries to rein in a spike in infections and help revive an economy that recorded its worst slump in more than two decades last year.’

Read here (Channel News Asia, Mar 2, 2021)

Covid-19: Pfizer BioNTech vaccine reduced cases by 94% in Israel, shows peer reviewed study

‘The Pfizer BioNTech coronavirus vaccine produces as good results in the “real world” as have been previously documented in randomised trials.

‘A case control study, which has been peer reviewed and published in the New England Journal of Medicine, compared 596 618 people who were newly vaccinated in Israel and matched them to unvaccinated controls.1 Two doses of the mRNA vaccine reduced symptomatic cases by 94%, hospitalisation by 87%, and severe covid-19 by 92%, according to the data from the Clalit Institute for Research which is Israel’s biggest healthcare provider.

‘Researchers recorded the outcomes at three periods: days 14 to 20 after the first dose of vaccine, days 21 through 27 after the first dose, and day 7 after the second dose. In Israel, the second dose of vaccine is given on day 21 in line with the trials and the manufacturer’s recommendation. The UK is leaving a 12 week gap between doses.

‘During a mean follow-up of 15 days, 10 561 infections were documented of which 5996 were symptomatic covid-19 illness, 369 required hospitalisation, 229 were severe cases, and 41 resulted in death.

‘After one dose, during days 14 to 20, the vaccine effectiveness was 57% for symptomatic covid-19, 74% for hospitalisation, and 62% for severe disease. The estimated effectiveness in preventing death from covid-19 was 72% in the two to three weeks after the first dose. There was insufficient data to produce an estimate on the reduction in mortality in those who received two doses.

‘The study took place from 20 December 2020, when Israel’s national vaccination drive was launched, to 1 February 2021. It coincided with Israel’s third and largest wave of coronavirus infection and illness.’

Read here (BMJ, Feb 25, 2021)

• BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting

Read original study here (New England Journal of Medicine, Feb 24, 2021)

Why Covid vaccines are so difficult to compare

‘Given the demand for speed amid limited supplies, any effort to rank the vaccines must take into account not only their reported effectiveness, but also supplies, costs, the logistics of deploying them, the durability of the protection they offer and their ability to fend off emerging viral variants. Even so, many people might find it hard to look away from clinical-trial results that suggest an efficacy gap. So far, more than 200 million doses of coronavirus vaccines have been delivered, and data have been rolling in from clinical trials in several countries. The top-line results from those studies suggest a range of protection: from 95% efficacy for a vaccine made by Pfizer of New York City and BioNTech of Mainz, Germany, to about 70% suggested by initial results on a vaccine made by AstraZeneca of Cambridge and the University of Oxford, both in the United Kingdom.’

Read here (Nature, Feb 23, 2021)

Israeli study finds 94% drop in symptomatic Covid-19 cases with Pfizer vaccine

‘Israel's largest healthcare provider on Sunday (Oct 14) reported a 94 per cent drop in symptomatic COVID-19 infections among 600,000 people who received two doses of the Pfizer's vaccine in the country's biggest study to date.

‘Health maintenance organization (HMO) Clalit, which covers more than half of all Israelis, said the same group was also 92 per cent less likely to develop severe illness from the virus.’

Read here (Channel News Asia, Feb 15, 2021)

Pfizer withdraws vaccine application in India [after failing to present needed information to experts]

‘Pfizer Inc says it has withdrawn its application for emergency use of its COVID-19 vaccine in India. The company said Friday that it participated in a meeting of experts of the drug regulator on Feb. 3. Based on the deliberation of that meeting and “our understanding of additional information that the regulator may need, the company has decided to withdraw its application at this time,” it said in a statement.

‘The company was the first to approach the Indian regulator in December for its messenger RNA vaccine that it has developed with Germany’s BioNTech. They were closely followed by applications for two other vaccines --- a version of the AstraZeneca made by Serum Institute of India and another by Indian company Bharat Biotech -- which eventually got the nod for emergency use on Jan. 3. However, India’s Health Ministry has said that Pfizer hadn’t made its presentation to experts who needed to clear the vaccine, before the regulator could green-light its use in India.’

Read here (The Independent, Feb 6, 2021)

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

‘It is important to note that all the severe Covid-19 cases were in the placebo group, which suggests that mRNA-1273 is likely to have an effect on preventing severe illness, which is the major cause of health care utilization, complications, and death. The finding of fewer occurrences of symptomatic SARS-CoV-2 infection after a single dose of mRNA-1273 is encouraging; however, the trial was not designed to evaluate the efficacy of a single dose, and additional evaluation is warranted.

‘Overall, the safety of the mRNA-1273 vaccine regimen and platform is reassuring; no unexpected patterns of concern were identified. The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. Overall, the local reactions to vaccination were mild; however, moderate-to-severe systemic side effects, such as fatigue, myalgia, arthralgia, and headache, were noted in about 50% of participants in the mRNA-1273 group after the second dose. These side effects were transient, starting about 15 hours after vaccination and resolving in most participants by day 2, without sequelae.’

Read here (New England Journal of Medicine, Feb 4, 2020)